Literature DB >> 33472427

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.

Hans Christoph Diener1, Messoud Ashina2, Isabelle Durand-Zaleski3,4, Tobias Kurth5, Michel Lantéri-Minet6, Richard B Lipton7, Daniel A Ollendorf8, Patricia Pozo-Rosich9,10, Cristina Tassorelli11,12, Gisela Terwindt13.   

Abstract

The Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine. Health technology assessments are systematic evaluations of the properties, effects, and consequences of healthcare technologies; this position statement is designed to inform decision makers about access to and reimbursement for medications and devices for the acute and preventive treatment of migraine. This position statement extends beyond the already available guidelines on randomized controlled trials for migraine to incorporate real-world evidence and a synthetic approach for considering multiple data sources and modelling methods when assessing the value of migraine treatments.

Entities:  

Keywords:  Health technology assessment (HTA); International Headache Society (IHS); acute therapy; migraine; position statement; preventive treatment

Mesh:

Year:  2021        PMID: 33472427      PMCID: PMC7961634          DOI: 10.1177/0333102421989247

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  68 in total

1.  Guidelines for controlled trials of drugs in migraine: second edition.

Authors:  P Tfelt-Hansen; G Block; C Dahlöf; H C Diener; M D Ferrari; P J Goadsby; V Guidetti; B Jones; R B Lipton; H Massiou; C Meinert; G Sandrini; T Steiner; P B Winter
Journal:  Cephalalgia       Date:  2000-11       Impact factor: 6.292

2.  The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.

Authors: 
Journal:  Headache       Date:  2018-12-10       Impact factor: 5.887

3.  Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis.

Authors:  R B Lipton; W F Stewart; D D Celentano; M L Reed
Journal:  Arch Intern Med       Date:  1992-06

4.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

5.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.

Authors: 
Journal:  Cephalalgia       Date:  2018-01       Impact factor: 6.292

6.  Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.

Authors:  Theodoros V Giannouchos; Dimos-Dimitrios Mitsikostas; Robert L Ohsfeldt; Athanassios Vozikis; Paraskevi Koufopoulou
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

Review 7.  Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

Authors:  S D Silberstein; S Holland; F Freitag; D W Dodick; C Argoff; E Ashman
Journal:  Neurology       Date:  2012-04-24       Impact factor: 9.910

8.  EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs.

Authors:  Megan R Stafford; Asha Hareendran; Daisy S Ng-Mak; Ralph P Insinga; Ruifeng Xu; Donald E Stull
Journal:  Health Qual Life Outcomes       Date:  2012-06-12       Impact factor: 3.186

9.  Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life - A Case Study of the Innovative Medicines Initiative.

Authors:  Michael Happich; Alan Brnabic; Douglas Faries; Keith Abrams; Katherine B Winfree; Allicia Girvan; Pall Jonsson; Joseph Johnston; Mark Belger
Journal:  Clin Pharmacol Ther       Date:  2020-05-30       Impact factor: 6.875

10.  Italian guidelines for primary headaches: 2012 revised version.

Authors:  Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin
Journal:  J Headache Pain       Date:  2012-05       Impact factor: 7.277

View more
  6 in total

1.  Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study.

Authors:  Pablo Irimia; David García-Azorín; Mercedes Núñez; Sílvia Díaz-Cerezo; Pepa García de Polavieja; Tommaso Panni; Aram Sicras-Navarro; Antoni Sicras-Mainar; Antonio Ciudad
Journal:  J Headache Pain       Date:  2022-07-07       Impact factor: 8.588

2.  Computerized migraine diagnostic tools: a systematic review.

Authors:  Yohannes W Woldeamanuel; Robert P Cowan
Journal:  Ther Adv Chronic Dis       Date:  2022-01-24       Impact factor: 5.091

3.  mBrain: towards the continuous follow-up and headache classification of primary headache disorder patients.

Authors:  Mathias De Brouwer; Nicolas Vandenbussche; Bram Steenwinckel; Marija Stojchevska; Jonas Van Der Donckt; Vic Degraeve; Jasper Vaneessen; Filip De Turck; Bruno Volckaert; Paul Boon; Koen Paemeleire; Sofie Van Hoecke; Femke Ongenae
Journal:  BMC Med Inform Decis Mak       Date:  2022-03-31       Impact factor: 2.796

4.  Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study.

Authors:  Maurice T Driessen; Joshua M Cohen; Oscar Patterson-Lomba; Stephen F Thompson; Michael Seminerio; Karen Carr; Todor I Totev; Rochelle Sun; Erica Yim; Fan Mu; Rajeev Ayyagari
Journal:  J Headache Pain       Date:  2022-04-11       Impact factor: 7.277

5.  A Digital Therapeutic Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from Two Prospective Studies.

Authors:  Vivian Valeska Lelleck; Franziska Schulz; Oliver Witt; Gianna Kühn; Dominik Klein; Astrid Gendolla; Stefan Evers; Charly Gaul; Diamant Thaçi; Christian Sina; Torsten Schröder
Journal:  Nutrients       Date:  2022-07-17       Impact factor: 6.706

6.  HIT-6 and EQ-5D-5L in patients with migraine: assessment of common latent constructs and development of a mapping algorithm.

Authors:  Tobias Kurth; Annette Aigner; Ana Sofia Oliveira Gonçalves; Dimitra Panteli; Lars Neeb
Journal:  Eur J Health Econ       Date:  2021-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.